Toll Free: 1-888-928-9744
Published: Mar, 2017 | Pages:
28 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Premenstrual Syndrome - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Premenstrual Syndrome - Pipeline Review, H1 2017, provides an overview of the Premenstrual Syndrome (Women's Health) pipeline landscape. Premenstrual syndrome (PMS) is a collection of physical and emotional symptoms related to a woman's menstrual cycle. Premenstrual syndrome has a wide variety of symptoms, including mood swings, tender breasts, food cravings, fatigue, irritability and depression. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Premenstrual Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Premenstrual Syndrome (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Premenstrual Syndrome (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Premenstrual Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 2 and 1 respectively. Premenstrual Syndrome (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Premenstrual Syndrome (Women's Health). - The pipeline guide reviews pipeline therapeutics for Premenstrual Syndrome (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Premenstrual Syndrome (Women's Health) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Premenstrual Syndrome (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Premenstrual Syndrome (Women's Health) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Premenstrual Syndrome (Women's Health). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Premenstrual Syndrome (Women's Health) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Premenstrual Syndrome - Overview Premenstrual Syndrome - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Premenstrual Syndrome - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Premenstrual Syndrome - Companies Involved in Therapeutics Development Asarina Pharma AB Pherin Pharmaceuticals Inc Premenstrual Syndrome - Drug Profiles estrogen + progesterone - Drug Profile Product Description Mechanism Of Action R&D Progress PH-80PMD - Drug Profile Product Description Mechanism Of Action R&D Progress sepranolone - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule 1 to Antagonize GABAA Receptor for PMDD - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule 2 to Antagonize GABAA Receptor for PMDD - Drug Profile Product Description Mechanism Of Action R&D Progress Premenstrual Syndrome - Dormant Projects Premenstrual Syndrome - Product Development Milestones Featured News & Press Releases Sep 19, 2014: Umecrine Mood announces positive results from an exploratory Phase I/II study with UC1010 in premenstrual dysphoric disorder (PMDD) Jun 12, 2014: Umecrine Mood reports preliminary data from exploratory Phase II study in premenstrual dysphoric disorder Dec 16, 2013: Patient recruitment completed in the Phase I/II study of Umecrine Mood's candidate drug for severe premenstrual symptoms May 23, 2013: Umecrine Mood Announces Dosing Of First Patient In Phase I/II Study Of UC1010 For Premenstrual Dysphoric Disorder Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Premenstrual Syndrome, H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Premenstrual Syndrome - Pipeline by Asarina Pharma AB, H1 2017 Premenstrual Syndrome - Pipeline by Pherin Pharmaceuticals Inc, H1 2017 Premenstrual Syndrome - Dormant Projects, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.